Next Article in Journal / Special Issue
Design Principles as a Guide for Constraint Based and Dynamic Modeling: Towards an Integrative Workflow
Previous Article in Journal
Using Gene Essentiality and Synthetic Lethality Information to Correct Yeast and CHO Cell Genome-Scale Models
Previous Article in Special Issue
Achieving Metabolic Flux Analysis for S. cerevisiae at a Genome-Scale: Challenges, Requirements, and Considerations
Review

Cancer Metabolism and Drug Resistance

1
Sidra Medical & Research Center, P.O. Box 26999 Doha, Qatar
2
Weill Cornell Medical College in Qatar, P.O. Box 24144 Doha, Qatar
*
Author to whom correspondence should be addressed.
Academic Editor: Kazuyuki Shimizu
Metabolites 2015, 5(4), 571-600; https://doi.org/10.3390/metabo5040571
Received: 28 August 2015 / Revised: 25 September 2015 / Accepted: 28 September 2015 / Published: 30 September 2015
(This article belongs to the Special Issue Metabolic Flux Analysis)
Metabolic alterations, driven by genetic and epigenetic factors, have long been known to be associated with the etiology of cancer. Furthermore, accumulating evidence suggest that cancer metabolism is intimately linked to drug resistance, which is currently one of the most important challenges in cancer treatment. Altered metabolic pathways help cancer cells to proliferate at a rate higher than normal, adapt to nutrient limited conditions, and develop drug resistance phenotypes. Application of systems biology, boosted by recent advancement of novel high-throughput technologies to obtain cancer-associated, transcriptomic, proteomic and metabolomic data, is expected to make a significant contribution to our understanding of metabolic properties related to malignancy. Indeed, despite being at a very early stage, quantitative data obtained from the omics platforms and through applications of 13C metabolic flux analysis (MFA) in in vitro studies, researchers have already began to gain insight into the complex metabolic mechanisms of cancer, paving the way for selection of molecular targets for therapeutic interventions. In this review, we discuss some of the major findings associated with the metabolic pathways in cancer cells and also discuss new evidences and achievements on specific metabolic enzyme targets and target-directed small molecules that can potentially be used as anti-cancer drugs. View Full-Text
Keywords: drug resistance; metabolic pathways; systems biology; metabolic flux analysis; antimetabolites; targeted therapy drug resistance; metabolic pathways; systems biology; metabolic flux analysis; antimetabolites; targeted therapy
Show Figures

Figure 1

MDPI and ACS Style

Rahman, M.; Hasan, M.R. Cancer Metabolism and Drug Resistance. Metabolites 2015, 5, 571-600. https://doi.org/10.3390/metabo5040571

AMA Style

Rahman M, Hasan MR. Cancer Metabolism and Drug Resistance. Metabolites. 2015; 5(4):571-600. https://doi.org/10.3390/metabo5040571

Chicago/Turabian Style

Rahman, Mahbuba, and Mohammad R. Hasan 2015. "Cancer Metabolism and Drug Resistance" Metabolites 5, no. 4: 571-600. https://doi.org/10.3390/metabo5040571

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop